Dr Kerryn A Moore
Research Fellow - Malaria & Infectious Diseases Ep
Melbourne School of Population and Global Health
46 Scholarly works
1 Projects
HIGHLIGHTS
2026
Journal article
The Malaria Vaccine Programme Evaluation in Kenya: results of a baseline household survey prior to the introduction of the RTS,S/AS01 vaccine
DOI: 10.1186/s12936-026-05911-22026
Journal article
The Malaria Vaccine Implementation Programme study area in Ghana: results of a household survey prior to the introduction of the RTS,S/AS01 vaccine
DOI: 10.1186/s12936-025-05778-92026
Journal article
Impact of introducing RTS,S/AS01E malaria vaccine on mortality in young children in Ghana, Kenya, and Malawi: an observational evaluation of a cluster-randomised implementation programme
DOI: 10.1016/S0140-6736(26)00248-52026
Journal article
Reduction of stillbirth rate in refugee and migrant populations living on the Thailand Myanmar border: A retrospective study 1986–2023
DOI: 10.1371/journal.pgph.00059832026
Journal article
Immunogenicity and efficacy over 12 months following a fourth dose of a bivalent mRNA or protein-based COVID-19 vaccine: A randomised controlled trial in Australia
DOI: 10.1016/j.jinf.2026.1067272026
Journal article
Fractional BNT162b2 boosters induce durable immune responses after non-mRNA priming in Mongolia: a randomised controlled trial
DOI: 10.3389/fimmu.2026.17892482024
Research grants (ARC, NHMRC, MRFF)
Epidemiological Evidence to Inform Policy on Optimal and Equitable Access to Pneumococcal Vaccination in the Asia-Pacific Region
RECENT SCHOLARLY WORKS
2026
Journal article
Cellular immune responses 12 months after fractional or standard dose BNT162b2 booster vaccination in Mongolian adults
DOI: 10.3389/fimmu.2026.17794352025
Journal article
Pneumococcal density and respiratory co-detection in severe pediatric pneumonia in Laos
DOI: 10.1038/s41598-025-01659-y2025
Journal article
Immunogenicity and safety at twelve months of fractional and standard BNT162b2 booster doses in adults primed with ChAdOx1-S, BBIBP-CorV, or Gam-COVID-Vac in Mongolia: a randomised controlled trial
DOI: 10.1016/j.vaccine.2025.1278402025
Journal article
The immunogenicity, reactogenicity, and safety of a bivalent mRNA or protein COVID-19 vaccine given as a fourth dose
DOI: 10.1016/j.jinf.2025.106447